CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates
CervoMed Inc. (CRVO) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to a loss of $0.8 per share a year ago.
CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates
CervoMed Inc. (CRVO) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to a loss of $0.55 per share a year ago.
CERVOMED INC (CRVO) Surges 11.6%: Is This an Indication of Further Gains?
CERVOMED INC (CRVO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates
CervoMed Inc. (CRVO) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.41 per share a year ago.
CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats
CervoMed's stock surged more than 400% after interim data showed significant improvement with a new batch of neflamapimod in treating Dementia with Lewy Bodies. The recent interim readout deserves excitement, but I do express several concerns related to, among others, potential learning and placebo effects, subjective CDR-SB results, and lack of biomarker data. CervoMed is well-funded into 2026, but may need additional funds for further trials to bring neflamapimod to market for DLB.
CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets
On Tuesday, CervoMed Inc. CRVO stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy bodies (DLB).
CervoMed's stock craters 77% after failed trial of treatment for rare brain disease
CervoMed Inc.'s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with dementia with Lewy bodies, or DLB, failed to meet its main goals.
CervoMed's dementia drug fails to meet mid-stage trial goals
U.S. drug developer CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary goals in a mid-stage clinical trial.
CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock?
CERVOMED INC (CRVO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
